Tirzepatide

tirzLY3298176Lyophilized powder

Tirzepatide is a once-weekly peptide that activates two incretin hormone receptors, GIP and GLP-1. Prescription medicines containing it are FDA-approved for type 2 diabetes and chronic weight management; the research-grade vials listed here are a different, unapproved product. Below: today's vial sizes, prices through our link and the vendor's COA details.

Size

$3.50/mg · lot GT10-062026-1 · 99.84% · In stock

Price

$35.00

List

$79.00

Buy 10 mg at Nura Peptide

Price shown uses code thepeptidecatalog at Nura Peptide's checkout (30% off list).

Sold by Nura Peptide as GLP-2T. The Peptide Catalog does not sell peptides; we earn a commission if you buy through this link, at no extra cost to you. For laboratory research use only, not for human or veterinary use. Not FDA-approved. Nothing on this page is medical or dosing advice.

Tirzepatide research vial sold by Nura Peptide as GLP-2T
Third-party tested≥99.82% reported purityResearch use only
Certificate of AnalysisLot GT10-062026-1 · 99.84% · 3 current lotsView
  • Certificate of Analysis published for every lot (Freedom Diagnostics Testing)
  • Current lots report 99.82% purity or higher
  • Ships from a U.S. fulfillment center, per Nura Peptide
  • Lyophilized powder · laboratory research use only
Research-context information only. Tirzepatide is the active ingredient in FDA-approved products for type 2 diabetes and chronic weight management; research-peptide and compounded forms are not FDA-approved and are sold for research purposes only. Protocols, doses, and reactions reported below come from clinical trials and community sources. This article reports what has been documented, not what should be done. Consult a licensed physician for personal medical decisions.

Vial sizes listed by the vendor

Tirzepatide Vial Sizes, Prices & Lots

Tirzepatide vial sizes, prices and lots at Nura Peptide
SizeListWith our codePer mgAvailabilityLot · purity
10 mg$79.00$35.00$3.50In stockGT10-062026-1 · 99.84%
30 mg$170.00$77.00$2.57In stockGT30-062026-1 · 99.82%
60 mg$155.00$108.50$1.81In stockGT60-062026-1 · 99.86%

Prices checked today, 6:20 AM CT on Nura Peptide's site, with code thepeptidecatalog applied. Lot data from Nura Peptide's COA page, checked today, 8:52 PM CT. Sizes not re-checked in the last 7 days are hidden. The vendor's checkout is final.

Verified test results

Tirzepatide Certificate of Analysis

Nura Peptide publishes a third-party certificate for each lot of GLP-2T. The figures below are copied from Nura Peptide's current-lot listings, checked today, 8:52 PM CT (refreshed hourly; hidden if older than 24 hours). Match the lot number on the vial to its certificate.

All lots on record: Nura Peptide COA library. How to check one: how to verify a peptide COA.

Tirzepatide Dosing in Clinical Research

Weight Loss / Diabetes

Educational reference only. Individual responses vary. Consult healthcare provider before use.

Vial Size
10 mg
Reconstitution
2 ml BAC water
Dose
0.5 mg (10 units on 1ml syringe)
Timing
AM
Frequency
3x per week
Duration
8 weeks on, 8 weeks off or until goal weight
Protocol Notes
Dual GIP/GLP-1 agonist. Best taken on empty stomach.

Why This Dosing Protocol

Why slow titration? Same principle as semaglutide — titrating from 2.5mg up through 5, 7.5, 10, 12.5, to 15mg over weeks minimizes GI side effects.

Why weekly? Extended half-life allows once-weekly injection with consistent efficacy throughout the week.
Full Dosing GuideReconstitution CalculatorCycle Cost Calculator
Popular Stack Protocols1 stack

Commonly paired protocols from the peptide research community. Educational reference only.

Semaglutide + Tirzepatide

Weight Loss (Sequential)
Semaglutide
Dose
250 mcg weekly
Vial Size
3 mg
Reconstitution
2 ml BAC water
Tirzepatide
Dose
0.5 mg 3x/week
Vial Size
10 mg
Reconstitution
2 ml BAC water
Timing
AM
Frequency
Sequential — not taken simultaneously
Duration
Until goal weight, then maintenance
NOT a simultaneous stack — these are sequential options. Start with semaglutide (GLP-1 only), and if plateauing, transition to tirzepatide (dual GIP/GLP-1) for stronger effects. Some protocols alternate. Never combine both simultaneously due to overlapping GLP-1 receptor agonism and compounding GI side effects.

How Tirzepatide Works: GIP & GLP-1 Receptors

Dual GIP/GLP-1 Receptor Agonist

Receptor → Metabolic Cascade → Weight & Glucose → Outcomes

1
Target

GIP + GLP-1 Receptors — Dual Incretin Activation

Tirzepatide is the first approved dual agonist, targeting both GIP and GLP-1 receptors simultaneously. This dual mechanism produces synergistic effects on appetite, insulin sensitivity, and fat metabolism that exceed what either pathway achieves alone.

2
Cellular Signal

Dual cAMP Activation → Enhanced Insulin + Satiety

GLP-1 receptor activation drives appetite suppression and insulin secretion. GIP receptor activation enhances fat metabolism and may improve beta cell function. The dual signal produces a metabolic effect greater than the sum of its parts.

3
Systemic Effect

Superior Appetite Control + Metabolic Optimization

Clinical trials show 20-25% body weight reduction — the highest of any approved medication. Enhanced glucose control often achieves near-normal A1C levels. The GIP component may help preserve lean mass during weight loss.

4
What You Notice

Strong Appetite Reduction → Exceptional Weight Loss

Appetite suppression is typically stronger than with semaglutide. Weight loss is steady and significant. GI side effects (nausea) are common during titration but generally manageable. Blood sugar normalization can be dramatic.

What Makes This Peptide Different

Tirzepatide's dual GIP/GLP-1 mechanism produces 20-25% weight loss — about 5% more than semaglutide alone. The GIP component adds metabolic benefits that pure GLP-1 agonists lack. It represents the next generation beyond semaglutide. The upcoming Retatrutide adds a third receptor (glucagon) for potentially even greater effects.

Tirzepatide Clinical Evidence

Two parallel grades per outcome — clinical RCT depth and real-world community adoption. See the Research Overview below for citations and detail.

OutcomeClinical EvidenceCommunity Evidence
Body weight reduction (obesity)StrongStrong
HbA1c reduction in T2DStrongStrong
Cardiovascular risk reductionModerateModerate
Obstructive sleep apneaModerateModerate
MASH resolutionModerateModerate

Tirzepatide Research Overview

Outcome-by-outcome look at what the evidence actually supports for Tirzepatide, including human vs. animal study counts and our editorial take on each.

Body weight reduction (obesity)

Clinical:StrongCommunity:Strong

SURMOUNT-1 demonstrated up to 22.5% mean body weight reduction at 72 weeks at the highest dose — established efficacy across multiple Phase 3 trials.

5 human studies · 8 animal studies

Key findings & citations
  • Mean weight loss of approximately 22.5% at 15 mg over 72 weeks.
  • Greater than 50% of participants achieved 20% body weight reduction.
  • Effect maintained across diabetic and non-diabetic populations.

Our take

Backed by the strongest weight-loss trial program of any approved therapy. Until retatrutide finishes Phase 3, this is the standard.

HbA1c reduction in T2D

Clinical:StrongCommunity:Strong

Across the SURPASS program, tirzepatide reduces HbA1c by 2–2.6 percentage points and outperforms semaglutide head-to-head.

6 human studies · 6 animal studies

Key findings & citations
  • HbA1c reduction of 2.0–2.6% across SURPASS-1 through SURPASS-5.
  • Outperformed semaglutide 1 mg in head-to-head SURPASS-2 trial.
  • Greater than 80% of participants reached HbA1c <7%.

Our take

Best-in-class glycemic control among approved incretin agents. Pricing and supply are the limiting factors, not efficacy.

Obstructive sleep apnea

Clinical:ModerateCommunity:Moderate

SURMOUNT-OSA showed roughly 25–30 events/hour reduction in apnea-hypopnea index in adults with obesity and moderate-to-severe OSA.

1 human study · 0 animal studies

Key findings & citations
  • AHI reduction of approximately 27 events/hour at 15 mg.
  • Greater than 40% of participants achieved disease remission criteria.
  • Effects driven primarily by weight loss — not a direct neuromuscular mechanism.

Our take

Major win for OSA management. Don't expect benefit independent of weight loss — it's the mechanism.

What Tirzepatide doesn't do

Claims that current evidence does not support. Worth knowing before you set expectations.

Technical specifications

Tirzepatide chemical & analytical data

Also known as
tirz, LY3298176
Sold by Nura Peptide as
GLP-2T
Receptor targets
GLP-1R / GIPR dual agonist
Backbone length
39 amino acids
Modifications
Aib at positions 2 and 13; C20 fatty acid acylation at Lys20
Half-life (clinical PK)
~5 days (weekly dosing)
Form
Lyophilized (freeze-dried) powder in a sealed vial
Presentation
10 mg · 30 mg · 60 mg
Purity on current lots (COA)
99.82% to 99.86%
Testing laboratory
Freedom Diagnostics Testing
Regulatory status
Active ingredient in FDA-approved prescription products; research-grade vials are not FDA-approved.

Tirzepatide Reconstitution Calculator

Dilution math and unit conversions. Prefilled using a common vial size for this peptide.

Open calculator

Storage & Handling

Storage at a glance

Proper storage temperatures, shelf life, reconstitution best practices, and travel tips for lyophilized and reconstituted peptides.

Powder: Freezer
1+ year at -20°C
Reconstituted: Fridge
4 weeks max at 2-8°C
View Complete Storage Guide

Handling specifics

Educational overview on storage, labeling, and traceability considerations for lab environments. Consult primary literature and vendor documentation for specifics.

Powder storage (very stable)
  • Freezer (-20°C): 1+ year
  • Refrigerator (2-8°C): 1-3 months
  • Room temperature: 2-3 weeks (emergency only)
Reconstituted storage (fragile)
  • MUST refrigerate at 2-8°C
  • 4-week maximum shelf life
  • NEVER freeze after reconstitution
  • Use bacteriostatic water for multi-dose

11 answers

Tirzepatide FAQ: Buying, COA, Storage & Research

Why is tirzepatide more effective than other weight loss medications?
Tirzepatide is a "dual agonist" — it activates both GIP and GLP-1 receptors, while other medications like semaglutide only target GLP-1. This dual action provides synergistic effects on appetite, glucose control, and fat burning, resulting in 20-25% weight loss in trials — the highest of any approved medication.
Is tirzepatide approved for both diabetes and weight loss?
Yes, tirzepatide is FDA-approved for both type 2 diabetes and chronic weight management in adults with obesity or overweight with weight-related conditions. The formulation is identical for both uses; they differ only in approved indication.
What are the side effects of tirzepatide?
Common side effects include nausea, diarrhea, decreased appetite, vomiting, and constipation. These are typically most pronounced during dose escalation and improve over time. GI effects may be more intense than with GLP-1-only medications due to the dual mechanism. Rare serious effects include pancreatitis and thyroid tumors (in animal studies).
How does tirzepatide compare to semaglutide?
Head-to-head trials show tirzepatide produces greater weight loss than semaglutide (about 5% more on average). Tirzepatide's dual GIP/GLP-1 action also tends to produce better blood sugar control. However, semaglutide has a longer safety track record. Both are effective; tirzepatide may be preferred when maximum weight loss is the priority.
What is GIP and why does adding it to GLP-1 help?
GIP (glucose-dependent insulinotropic polypeptide) is an incretin hormone like GLP-1. While GLP-1 primarily reduces appetite, GIP enhances insulin secretion and may directly affect fat tissue. Together they provide complementary mechanisms: better appetite control, improved glucose handling, and potentially enhanced fat metabolism.
What is the typical tirzepatide dosing schedule?
A common research dosage is 0.5 mg (10 units on 1ml syringe) administered 3 times per week in the AM. Protocol: 8 weeks on, 8 weeks off or until goal weight is reached. Best taken on an empty stomach.
How much weight can I expect to lose on tirzepatide?
Clinical trials showed average weight loss of 20-22% of body weight at higher doses over 72 weeks. Some participants lost over 25%. This is the highest weight loss achieved by any approved medication. Results vary based on dose, diet, exercise, and individual response.
Is tirzepatide available as a compounded medication?
Due to FDA-approved brand shortages, compounding pharmacies have produced tirzepatide. However, the FDA has updated shortage lists, which affects compounding legality. Always verify current regulations and source from reputable providers. The FDA-approved versions remain the standard.
How long does reconstituted peptide last?
Once mixed with bacteriostatic water, peptides remain stable for up to 4 weeks when refrigerated at 2-8°C (36-46°F). Unopened powder can last 1+ year in the freezer. Get our complete Storage & Travel Guide.
Is this peptide legal to purchase?
Peptides sold "for research purposes only" are legal to purchase in the US, but are not FDA-approved for human use outside of specific medical applications. Always consult a healthcare provider before use.
New to peptides?
Take our Peptide Match tool to find the best peptide for your goals. You can also read our Complete Guide to Peptides to learn the basics.

Tirzepatide Studies & Sources

The following peer-reviewed studies and official resources provide additional scientific context for this peptide:

Tirzepatide Research Articles

guides

Tirzepatide Dosage Chart: 0.5mg 3x/Week Protocol

Split dosing cuts GI side effects vs once-weekly — here's the math. Covers 0.5mg 3x/week, titration, and reconstitution.

weight-loss

Switching Tirzepatide to Retatrutide: Dose & Washout

How long tirzepatide takes to clear, what retatrutide dose trials started at, and what weeks 1-8 look like. Trial data plus community-reported protocols.

comparison

Orforglipron vs Tirzepatide: Pill or Shot?

Orforglipron is a daily pill, tirzepatide a weekly shot — but trials show the injection lost nearly twice the weight. The honest tradeoff, side by side.

articles

Best Peptides for Liver Health

In trials, semaglutide resolved MASH in 63% of patients — but where do BPC-157 and glutathione really stand? Every liver peptide, evidence-graded.

Compare Tirzepatide to alternatives

Side-by-side mechanism, dose, half-life, and vendor pricing.

Open compare →

Compare Tirzepatide Vendors Before You Buy

Disclosure: we may earn affiliate commission from qualifying purchases. Educational information only — not medical advice.